TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06567158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet
Description: During the moderate carbohydrate diet, participants will be asked to limit his/her carbohydrate intake to no more than 30% of their total energy intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet
Description: During the moderate carbohydrate diet, participants will be asked to limit his/her carbohydrate intake to no more than 30% of their total energy intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional diet
Description: During the traditional diet, participants do not follow any diet, however their carbohydrate intake must be at least 50% of their total energy intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional diet
Description: During the traditional diet, participants do not follow any diet, however their carbohydrate intake must be at least 50% of their total energy intake.
Study: NCT06310473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 10mg/kg intravenous (IV) every 3 weeks ;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m², iv drip for 2h, d1, q3w;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m² po, Bid, d1-14, q3w ;
Study: NCT05177237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar: 210 mg (14 PCS) continuous infusion for 168h, Q3W, 4 cycles. Methylprednisolone: 80mg intravenously, once daily, for 3-5 days, gradually reduced to 10mg/ day oral maintenance dose.
Study: NCT05188027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Walking at 60% of maximal aerobic capacity on a treadmill
Study: NCT06356714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens
Description: Nocardia Rubra Cell Wall Skeleton 200 mcg-400 mcg, 0.3 ml diluted in water for injection or lidocaine, was injected subcutaneously every 2 or 3 weeks.~Efficacy was evaluated every 2 cycles according to RECIST 1.1 criteria. Patients are enrolled and given this study regimen of drugs on top of their prior second- or third-line regimen until disease progression or intolerable toxicities occur; or the patient requests to be discharged.
Study: NCT05188027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Performing one set of 10 repetitions of 10 different weight-lifting exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No exercise
Description: Participants will rest in a supine position for 30 minutes.
Study: NCT06171217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression
Study: NCT04472065

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: 1 chewable tablet of probiotic dietary supplement (200 million CFU of L. reuteri DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 chewable placebo tablet containing all the same ingredients except L. reuteri (DSM 17938 and ATCC PTA 6475) consumed once per day orally for 6 weeks beginning at Baseline (between 1 to 3 days postpartum) to 6 weeks postpartum.
Study: NCT04891536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salvage cryoablation of the prostate (SCAP)
Description: Cryotherapy of the prostate through transperineal freeezing needles
Study: NCT05614388

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 Self testing and related messaging
Description: Provisioning of voluntary, free self-testing for COVID-19 (approved and validated in the country) and related Information, Education and Communication (IEC) messages
Study: NCT03821831

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: CPAP machine

Intervention type: DEVICE
Intervention: Orthodontic intervention
Description: Mandibular advancement or Rapid maxillary expansion devices
Study: NCT04701476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TATE and pembrolizumab
Description: All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TATE and pembrolizumab
Description: All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102 pill
Description: The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib Pill
Description: As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
Study: NCT05473858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OraVerse Injectable Product
Description: injection of oraverse,
Study: NCT06074094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Test
Description: Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Test
Description: Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients
Study: NCT05473858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: patient exposed to diode laser
Study: NCT06309615

Intervention type: OTHER
Intervention: Standard of Care
Description: To use the patients age, tumor size, grade, and lymph node status and any genomic tests (i.e. OncotypeDx, MammaPrint etc to determine risk of recurrence,

Intervention type: OTHER
Intervention: Standard of Care
Description: To use the patients age, tumor size, grade, and lymph node status and any genomic tests (i.e. OncotypeDx, MammaPrint etc to determine risk of recurrence,
Study: NCT05312255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Wear a FitBit device and receive prompts for 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Wear a FitBit device and receive prompts for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-Adrenergic Antagonist
Description: Receive beta-blocker regimen as per SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Undergo strength training for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Undergo strength training for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-Term Fasting
Description: Participate in intermittent fasting
Study: NCT05104736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT-112
Description: PT-112 will be administered intravenously in 28-day cycles, on Days 1 and 15 at a dose of 360 mg/m2 for cycle 1, and on day 1 at 250mg/m2 for each subsequent cycle,
Study: NCT06377969

Intervention type: DEVICE
Group type: OTHER
Intervention: ECAP (Evoked Compound Action Potential)-controlled Closed-Loop Spinal Cord Stimulation
Description: The patients will receive externalized epidural leads connected to external pulse generator for 5-14 days during trial phase. If the trial results in \>50% reduction in pain, they will undergo a minor surgery to receive implantable spinal cord stimulator
Study: NCT05925569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice Advisory Computerized Alert
Description: For patients randomly assigned to the BPA Alert Group, an on-screen electronic alert will be issued during the outpatient clinical encounter than notifies the clinician that their patient should be screened for PA. The clinician will be provided with on-screen details of which patient-specific risk factors qualified them for PA screening and with an option to order a plasma renin activity, aldosterone, and basic metabolic panel. If screening labs are ordered, the clinician will also receive an option to order an eConsult for expert guidance on interpretation of the test results. If the clinician does not order the PA screening labs, they will be able to continue with clinical EHR documentation but will need to select a reason they opted not to follow the alert's evidence-based clinical practice recommendation.
Study: NCT05699811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-IFNα
Description: MSC-IFNα form a dose of 2×10\^6 cells/kg, intravenous infusion every 4-6 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-IFNα
Description: MSC-IFNα form a dose of 2×10\^6 cells/kg, intravenous infusion every 4-6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125mg/m2, intravenous infusion every 4-6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200mg/m2, intravenous infusion every 4-6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: 200mg, intravenous infusion every 4-6 weeks
Study: NCT06057389

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: aronia melanocarpa extract
Description: aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst；twice a day，one at a time) combined with an energy-restricted diet
Study: NCT06293573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Description: GROUP A : will receive whole body vibration exercises combined with resistance exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercises
Description: Group B will receive aerobic exercises training combined with progressive resistance exercises with diet modification life style.
Study: NCT06057389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: aronia melanocarpa extract
Description: aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst；twice a day，one at a time) combined with an energy-restricted diet
Study: NCT06532682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: dapagliflozin 5 MG/10 MG once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: dapagliflozin 5 MG/10 MG once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: ACE inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Description: ACE inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Description: ACE inhibitor
Study: NCT05561959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical glyceryl trinitrate gel
Description: topical nitroglycerin medication were treated with 1 gr nitroglycerin 2% gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercises
Description: stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee).
Study: NCT06293573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercises
Description: Group c: will receive progressive resistance exercises with diet modification life style.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance exercises
Description: Group c: will receive progressive resistance exercises with diet modification life style.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercises
Description: Group c: will receive progressive resistance exercises with diet modification life style.
Study: NCT06439264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bentonite clay gel with hydroxyapatite
Description: bentonite clay gel presents great potential for bone healing and it leads to the formation of interconnected microporous structure, which can promote native cell infiltration, proliferation,
Study: NCT04741568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental psychoeducational Intervention
Description: The psychoeducation intervention for parents will focus on providing skills, knowledge and support motivation for caregivers of children with diabetes.~A brief (one-day or two half days) workshop, and a website with downloadable content will be made available to review and refresh any skills and techniques.
Study: NCT04916639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Physiomer undiluted seawater nasal spray
Description: In this study, subjects are asked to adhere to the following dosage during the 3 weeks of the study:~* Nasal wash four times every day~* These washes are to be carried out in each nostril~* By continuously pressing the spray for 3 seconds in each nostril~* Subjects are recommended to distribute the 4 nasal washes as follows:~  * 1st : morning~ * 2nd : midday~ * 3rd : afternoon~ * 4th : evening Subjects will be instructed to maintain daily nasal wash over the 3 weeks study period even in case of earlier nasal symptoms resolution, in order to assess the impact of nasal wash on viral load and other symptoms.
Study: NCT05941650

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short Chain Fructooligosaccharides
Description: The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corn Starch
Description: This group will receive 12 g of corn starch as a control group.
Study: NCT06525883

Intervention type: OTHER
Intervention: No intervation
Description: No intervention was made to the groups

Intervention type: OTHER
Intervention: No intervation
Description: No intervention was made to the groups
Study: NCT06439264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bentonite clay gel with hydroxyapatite
Description: bentonite clay gel presents great potential for bone healing and it leads to the formation of interconnected microporous structure, which can promote native cell infiltration, proliferation,
Study: NCT04753918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer sodium
Description: Photofrin 2mg/kg was iv injected 48-50 hours before light illumination.
Study: NCT06525883

Intervention type: OTHER
Intervention: No intervation
Description: No intervention was made to the groups
Study: NCT06461858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cuevas medek technique (exercise)
Description: The first group, known as the experimental group, group A, receives Cuevas Medek exercises once a week, for 45 minutes per session,for 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Group B, referred to as the conventional therapy group (Routine physical therapy), follows a regimen of conventional therapy once a week for 6 weeks for 20 mints.
Study: NCT04753918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethiodized oil
Description: In hybrid operation room setting, a navigational bronchoscope guide sheath was inserted to the proximal end of the tumor region. About 5 ml Lipiodol was infused to full cover whole the tumor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Novel light delivery methods of photodynamic therapy
Description: Using high-refraction index contrast medium: lipiodol as a light diffusor to enhance the range of photodynamic therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiber optic
Description: A cylindrical laser fiber was then inserted through the guide sheath to the tumor region then illuminate light to complete the photodynamic therapy.
Study: NCT05959707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01.23LS
Description: VRC01.23LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01.23LS
Description: VRC01.23LS will be administered IV over approximately 30 to 60 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01.23LS
Description: VRC01.23LS will be administered IV over approximately 30 to 60 minutes.
Study: NCT04587869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Coping Intervention
Description: A cognitive behavior therapy group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
Study: NCT05978882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel navigation surgery using fluorescence
Description: If the frozen biopsy of sentinel lymph nodes are all negative using fluorescence, stomach-preserving surgery is performed
Study: NCT06529679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-belt Training
Description: Walking on a split-belt treadmill in which the speed of one belt will be different (move faster or slower) than the speed of the other belt.
Study: NCT05865782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schoolyard reconstruction
Description: The current study will be designed as a quasi-experimental stepped-wedge intervention where schools undertaking schoolyard reconstruction will act as both control and intervention schools. By using the stepped-wedge study design, with internal control schools, will enable the control for the seasonal variation in children's physical activity levels and for the age-related decline in physical activity throughout childhood. That is, without control schools we would be unable to attribute a change in physical activity to the reconstruction of the schoolyards - as any difference in physical activity before and after the schoolyard reconstruction in the intervention group could be explained by the natural change in physical activity over time.
Study: NCT06529679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-belt Training
Description: Walking on a split-belt treadmill in which the speed of one belt will be different (move faster or slower) than the speed of the other belt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tied-Belt Training
Description: Walking on a split-belt treadmill in which the speed of both belts is the same.
Study: NCT05686343

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography, Doppler ultrasonography, Near-infrared spectroscopy
Description: Ecocardiography at 1st, 3rd and 7th day of life Doppler US (cranial and renal) at 1st, 3rd and 7th day of life Near-infrared spectroscopy monitoring after birth during first 3-days of life
Study: NCT06529679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tied-Belt Training
Description: Walking on a split-belt treadmill in which the speed of both belts is the same.
Study: NCT04871932

Intervention type: BIOLOGICAL
Intervention: Recently Vaccination

Intervention type: BIOLOGICAL
Intervention: Recently Vaccination
Study: NCT04809545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acusticare
Description: Acusticare is an internet connected speaker which delivers an environmental intervention by playing sounds to adjust the soundscape in the room.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Usual care provided on the Specialized Dementia Unit
Study: NCT05807555

Intervention type: OTHER
Intervention: Ambulatory ECG
Description: 24h ECG monitoring

Intervention type: OTHER
Intervention: Ambulatory ECG
Description: 24h ECG monitoring

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: The usual biological tests necessary for the management of the child and the addition of 1 tube of 2 ml
Study: NCT06537570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery Practice
Description: Before the guided imagery application, the language translation of the guided imagery usage steps guide prepared by Owen (2010)27 was done by a translation center in a certified manner. Then, a relaxing, soothing, soft and slow-paced CD consisting of mixed nature sounds, photographs and music lasting 15 minutes and 50 seconds was prepared in the sound recording studio with the psychological counselor.~Data collection forms were filled in by the researcher using face-to-face interview technique for the women who agreed to participate in the study. The guided imagery video was shared with the women and they were made to watch it once a day for 12 weeks in a quiet, calm, uncrowded, dimly lit room in their homes. The women in the control group did not receive any interventions other than routine interventions during outpatient follow-up.
Study: NCT05874843

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thromboelastography (TEG 6S)
Description: The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.